Raymond James Upgrades uniQure (NASDAQ:QURE) to Strong-Buy

Raymond James upgraded shares of uniQure (NASDAQ:QURE) from an outperform rating to a strong-buy rating in a report issued on Tuesday morning, MarketBeat reports. Raymond James currently has $52.00 target price on the biotechnology company’s stock, up from their previous target price of $20.00.

QURE has been the subject of several other research reports. Royal Bank of Canada reduced their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group dropped their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a research note on Thursday, October 17th. Cantor Fitzgerald lifted their target price on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of uniQure in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average target price of $27.33.

uniQure Stock Up 109.6 %

Shares of uniQure stock opened at $15.30 on Tuesday. uniQure has a twelve month low of $3.73 and a twelve month high of $17.39. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company’s 50 day moving average is $6.42 and its 200 day moving average is $6.15. The company has a market cap of $745.72 million, a price-to-earnings ratio of -3.08 and a beta of 0.89.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. Research analysts anticipate that uniQure will post -3.74 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.74% of the stock is currently owned by company insiders.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. abrdn plc boosted its stake in uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the period. Franklin Resources Inc. bought a new position in shares of uniQure during the third quarter worth $7,360,000. Vanguard Group Inc. boosted its position in shares of uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after acquiring an additional 109,740 shares during the last quarter. Point72 Asset Management L.P. grew its stake in uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares in the last quarter. Finally, Privium Fund Management B.V. increased its holdings in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.